Enterococcus faecalis resistant to linezolid: case series and review of the literature

Brian S Burleson1, David J Ritchie, Scott T Micek

  • 1Department of Pharmacy Practice, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, Texas, USA.

Pharmacotherapy
|October 6, 2004
PubMed

Insights

Reports of linezolid resistance in Enterococcus faecalis are rare but linked to extended linezolid therapy. This study identified three cases, highlighting the need to verify linezolid sensitivity in patients with recent or prolonged treatment.

Area of Science:

  • Medical Microbiology
  • Infectious Diseases
  • Antimicrobial Resistance

Background:

  • Linezolid is a crucial antibiotic for treating infections caused by Gram-positive bacteria, including resistant strains.
  • Reports of linezolid resistance in Enterococcus faecalis have been infrequent, making emerging resistance a significant concern.

Observation:

  • Three patients developed linezolid-resistant Enterococcus faecalis after prolonged (>30 days) linezolid treatment.
  • All resistant strains harbored the G2576U mutation in the 23S rRNA gene.
  • A literature review identified additional cases in the US and Europe, all associated with extended linezolid therapy.

Findings:

  • Extended or recent linezolid therapy appears to be a risk factor for the development of linezolid-resistant Enterococcus faecalis.
  • The G2576U mutation in 23S rRNA is associated with linezolid resistance in these strains.

Implications:

  • Clinicians should verify linezolid sensitivity in patients with new systemic enterococcal isolates who have recently undergone linezolid therapy.
  • Monitoring for linezolid resistance is crucial in patients experiencing breakthrough enterococcal infections during linezolid treatment.
  • This underscores the importance of judicious antibiotic use and resistance surveillance.

Related Concept Videos

Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Development of Antibiotic Resistance01:30

Development of Antibiotic Resistance

Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...